Link Details
| ID: | 1847 |
| Title: | Combining Cancer Drugs To Prevent Emergence Of The Drug-Resistant Forms Of BCR-ABL - http://www.medicalnewstoday.com/articles/79931.php |
| Pagerank: | N/A |
| Description: | Individuals with chronic myeloid leukemia (CML) are treated first with a drug known as imatinib (Gleevec), which targets the protein known to cause the cancer (BCR-ABL). If their disease returns, because BCR-ABL mutants emerge that are resistant to the effects of imatinib, individuals are treated with a drug known as dasatinib (SPRYCEL), which targets BCR-ABL in a different way. [click link for full article] |
| Category: | |
| Link Owner: | |
| Date Added: | August 20, 2007 02:00:00 AM |
| Number Hits: | 0 |